Phase-Change nanoparticles using highly volatile perfluorocarbons: Toward a platform for extravascular ultrasound imaging

Terry O Matsunaga, Paul S. Sheeran, Samantha Luois, Jason E. Streeter, Lee B. Mullin, Bhaskar Banerjee, Paul A. Dayton

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Recent efforts using perfluorocarbon (PFC) nanoparticles in conjunction with acoustic droplet vaporization has introduced the possibility of expanding the diagnostic and therapeutic capability of ultrasound contrast agents to beyond the vascular space. Our laboratories have developed phase-change nanoparticles (PCNs) from the highly volatile PFCs decafluorobutane (DFB, bp =-2 °C) and octafluoropropane (OFP, bp =-37 °C ) for acoustic droplet vaporization. Studies with commonly used clinical ultrasound scanners have demonstrated the ability to vaporize PCN emulsions with frequencies and mechanical indices that may significantly decrease tissue bioeffects. In addition, these contrast agents can be formulated to be stable at physiological temperatures and the perfluorocarbons can be mixed to modulate the balance between sensitivity to ultrasound and general stability. We herein discuss our recent efforts to develop finely-tuned diagnostic/molecular imaging agents for tissue interrogation. We discuss studies currently under investigation as well as potential diagnostic and therapeutic paradigms that may emerge as a result of formulating PCNs with low boiling point PFCs.

Original languageEnglish (US)
Pages (from-to)1185-1198
Number of pages14
JournalTheranostics
Volume2
Issue number12
DOIs
StatePublished - 2012

Fingerprint

Fluorocarbons
Nanoparticles
Ultrasonography
Volatilization
perflutren
Acoustics
Contrast Media
Molecular Imaging
Diagnostic Imaging
Emulsions
Blood Vessels
Temperature
Therapeutics

Keywords

  • Acoustic droplet vaporization
  • Diagnostic
  • Extravascular imaging
  • Perfluorocarbon
  • Phase-change nanoparticles
  • Therapeutic
  • Ultrasound

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Phase-Change nanoparticles using highly volatile perfluorocarbons : Toward a platform for extravascular ultrasound imaging. / Matsunaga, Terry O; Sheeran, Paul S.; Luois, Samantha; Streeter, Jason E.; Mullin, Lee B.; Banerjee, Bhaskar; Dayton, Paul A.

In: Theranostics, Vol. 2, No. 12, 2012, p. 1185-1198.

Research output: Contribution to journalArticle

Matsunaga, Terry O ; Sheeran, Paul S. ; Luois, Samantha ; Streeter, Jason E. ; Mullin, Lee B. ; Banerjee, Bhaskar ; Dayton, Paul A. / Phase-Change nanoparticles using highly volatile perfluorocarbons : Toward a platform for extravascular ultrasound imaging. In: Theranostics. 2012 ; Vol. 2, No. 12. pp. 1185-1198.
@article{515ae3623d304e83a19a99b64e2e2631,
title = "Phase-Change nanoparticles using highly volatile perfluorocarbons: Toward a platform for extravascular ultrasound imaging",
abstract = "Recent efforts using perfluorocarbon (PFC) nanoparticles in conjunction with acoustic droplet vaporization has introduced the possibility of expanding the diagnostic and therapeutic capability of ultrasound contrast agents to beyond the vascular space. Our laboratories have developed phase-change nanoparticles (PCNs) from the highly volatile PFCs decafluorobutane (DFB, bp =-2 °C) and octafluoropropane (OFP, bp =-37 °C ) for acoustic droplet vaporization. Studies with commonly used clinical ultrasound scanners have demonstrated the ability to vaporize PCN emulsions with frequencies and mechanical indices that may significantly decrease tissue bioeffects. In addition, these contrast agents can be formulated to be stable at physiological temperatures and the perfluorocarbons can be mixed to modulate the balance between sensitivity to ultrasound and general stability. We herein discuss our recent efforts to develop finely-tuned diagnostic/molecular imaging agents for tissue interrogation. We discuss studies currently under investigation as well as potential diagnostic and therapeutic paradigms that may emerge as a result of formulating PCNs with low boiling point PFCs.",
keywords = "Acoustic droplet vaporization, Diagnostic, Extravascular imaging, Perfluorocarbon, Phase-change nanoparticles, Therapeutic, Ultrasound",
author = "Matsunaga, {Terry O} and Sheeran, {Paul S.} and Samantha Luois and Streeter, {Jason E.} and Mullin, {Lee B.} and Bhaskar Banerjee and Dayton, {Paul A.}",
year = "2012",
doi = "10.7150/thno.4846",
language = "English (US)",
volume = "2",
pages = "1185--1198",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "12",

}

TY - JOUR

T1 - Phase-Change nanoparticles using highly volatile perfluorocarbons

T2 - Toward a platform for extravascular ultrasound imaging

AU - Matsunaga, Terry O

AU - Sheeran, Paul S.

AU - Luois, Samantha

AU - Streeter, Jason E.

AU - Mullin, Lee B.

AU - Banerjee, Bhaskar

AU - Dayton, Paul A.

PY - 2012

Y1 - 2012

N2 - Recent efforts using perfluorocarbon (PFC) nanoparticles in conjunction with acoustic droplet vaporization has introduced the possibility of expanding the diagnostic and therapeutic capability of ultrasound contrast agents to beyond the vascular space. Our laboratories have developed phase-change nanoparticles (PCNs) from the highly volatile PFCs decafluorobutane (DFB, bp =-2 °C) and octafluoropropane (OFP, bp =-37 °C ) for acoustic droplet vaporization. Studies with commonly used clinical ultrasound scanners have demonstrated the ability to vaporize PCN emulsions with frequencies and mechanical indices that may significantly decrease tissue bioeffects. In addition, these contrast agents can be formulated to be stable at physiological temperatures and the perfluorocarbons can be mixed to modulate the balance between sensitivity to ultrasound and general stability. We herein discuss our recent efforts to develop finely-tuned diagnostic/molecular imaging agents for tissue interrogation. We discuss studies currently under investigation as well as potential diagnostic and therapeutic paradigms that may emerge as a result of formulating PCNs with low boiling point PFCs.

AB - Recent efforts using perfluorocarbon (PFC) nanoparticles in conjunction with acoustic droplet vaporization has introduced the possibility of expanding the diagnostic and therapeutic capability of ultrasound contrast agents to beyond the vascular space. Our laboratories have developed phase-change nanoparticles (PCNs) from the highly volatile PFCs decafluorobutane (DFB, bp =-2 °C) and octafluoropropane (OFP, bp =-37 °C ) for acoustic droplet vaporization. Studies with commonly used clinical ultrasound scanners have demonstrated the ability to vaporize PCN emulsions with frequencies and mechanical indices that may significantly decrease tissue bioeffects. In addition, these contrast agents can be formulated to be stable at physiological temperatures and the perfluorocarbons can be mixed to modulate the balance between sensitivity to ultrasound and general stability. We herein discuss our recent efforts to develop finely-tuned diagnostic/molecular imaging agents for tissue interrogation. We discuss studies currently under investigation as well as potential diagnostic and therapeutic paradigms that may emerge as a result of formulating PCNs with low boiling point PFCs.

KW - Acoustic droplet vaporization

KW - Diagnostic

KW - Extravascular imaging

KW - Perfluorocarbon

KW - Phase-change nanoparticles

KW - Therapeutic

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=84878541793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878541793&partnerID=8YFLogxK

U2 - 10.7150/thno.4846

DO - 10.7150/thno.4846

M3 - Article

C2 - 23382775

AN - SCOPUS:84878541793

VL - 2

SP - 1185

EP - 1198

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 12

ER -